Disclosures: Ken Liu: Nothing to Disclose, Simone Chin: Nothing to Disclose, Charlotte Kench: Nothing to Disclose, Rena Cao: Nothing to Disclose, Christina Lee: Nothing to Disclose, Claire West: Nothing to Disclose, Susan Virtue: Nothing to Disclose, Talal Valliani: Nothing to Disclose, David Bowen: Nothing to Disclose, Simone Strasser: Chiesi: Advisor, Roche Diagnostics: Advisor, Roche Therapeutics: Advisor, Norgine: Speaking and Teaching, Abbott Diagnostics: Advisor, CSL Behring: Advisor, Novo Nordisk: Advisor, Astra Zeneca: Advisor, Sirtex: Speaking and Teaching, Eisai: Speaking and Teaching, GEOFF McCaughan: Nothing to Disclose 1690 MORTALITY IMPROVEMENT IN CIRRHOTIC AND HEPATOCELLULAR CARCINOMA PATIENTS WITH MAJOR DISCREPANCIES ACCORDING TO ETIOLOGY: A 10-YEAR NATIONWIDE STUDY Claire DELACOTE 1 Xavier Lenne 2 Alexandre LOUVET 3 Line Ntandja Wandji 4 Amlie BRUANDET 5 Sylvie Deuffic-Burban 6 Philippe Mathurin 4 , 1 Inserm, CHU Lille, Universit de Lille, U1286 INFINITE, 2 CHU Lille, DIM, 3 CHU Lille, Hpital Claude Huriez, Service des maladies de l'appareil digestif, 4 CHU de Lille, Hpital Claude Huriez, Service des maladies de l'appareil digestif, 5 CHU de Lille, DIM, 6 Universit Paris Cit and Universit Sorbonne Paris Nord, Inserm, IAME Background: Use of direct antiviral agents (DAA), growing burden of metabolic syndrome (MS) and changes in alcohol per capita require to investigate evolution of mortality in patients with cirrhosis and / or hepatocellular carcinoma (HCC)
JAMA 2018, 320 (13), 1307
Mar;110(3):774-80
Understanding their mechanistic distinctions is important for designing research protocols
Figure 9-7 shows the -mL and the 1-mL tuberculin syringes
